U.S. markets close in 3 hours 40 minutes
  • S&P 500

    4,107.14
    -29.34 (-0.71%)
     
  • Dow 30

    33,810.57
    -115.44 (-0.34%)
     
  • Nasdaq

    11,902.16
    -104.80 (-0.87%)
     
  • Russell 2000

    1,960.43
    -25.10 (-1.26%)
     
  • Crude Oil

    73.79
    +0.40 (+0.55%)
     
  • Gold

    1,879.10
    +2.50 (+0.13%)
     
  • Silver

    22.25
    -0.15 (-0.67%)
     
  • EUR/USD

    1.0722
    -0.0075 (-0.70%)
     
  • 10-Yr Bond

    3.6320
    +0.1000 (+2.83%)
     
  • GBP/USD

    1.2014
    -0.0043 (-0.36%)
     
  • USD/JPY

    132.8300
    +1.6800 (+1.28%)
     
  • BTC-USD

    23,004.90
    -24.94 (-0.11%)
     
  • CMC Crypto 200

    528.81
    +3.67 (+0.70%)
     
  • FTSE 100

    7,836.71
    -65.09 (-0.82%)
     
  • Nikkei 225

    27,693.65
    +184.19 (+0.67%)
     

Moderna Says COVID-19 Vax Associated With Fewer Cases Than Pfizer's, But Higher Inflammatory Heart Conditions

  • Moderna Inc (NASDAQ: MRNA) defended using its COVID-19 vaccine, saying the protection it offers outweighs the risk of myocarditis seen in a small number of young men who received the shot, reports CNBC.

  • The FDA last week said it requires more time to decide whether to authorize Moderna's vaccine for use in children ages 12 to 17.

  • Reported cases of rare heart inflammation in men under age 30 are relatively higher after Moderna's vaccine than those who received Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) shot, Moderna Chief Medical Officer Dr. Paul Burton told reporters on a call Thursday.

  • Related Link: EMA's Committee To Assess Further Data On Risk Of Heart Inflammation With mRNA COVID-19 Vaccines.

  • Burton cited data from France on males ages 12 to 29. It showed 13.3/100,000 cases of myocarditis for Moderna's vaccine compared with 2.7 cases for the Pfizer vaccine.

  • However, Burton also touted data from the Centers for Disease Control and Prevention that showed the rates of mild or severe disease were lower in Moderna recipients than in those who received Pfizer's or Johnson & Johnson's (NYSE: JNJ) vaccines.

  • Price Action: MRNA shares are down 2.34% at $223.75 during the market session on the last check Thursday.

  • Image by Spencer Davis from Pixabay

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.